You have read all your free articles, to continue reading subscribe to read the rest of this content.
Swedish Orphan Biovitrum (Sobi) has announced results from its phase 3 study of avatrombopag, an oral thrombopoietin (TPO) receptor agonist, in solid tumour cancer patients with chemotherapy-induced thrombocytopenia (CIT). Though avatrombopag increased platelet counts relative to placebo as expecAlready a subscriber Login You have read all your free articles, to…
Immunicum raises SEK 351M in a directed issue and a fully guaranteed rights issue for continued clinical development of Ilixadencel - a new cancer immunotherapy. On 16 October 2018, the Board of Immunicum AB decided to implement a directed issue of approximately SEK 178M (the "Directed Issue") anAlready a subscriber…
Medimmune and Sanofi Pasteur have announced an agreement to develop and commercialise MEDI8897, a monoclonal antibody (mAb) for the prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV,) jointly. MEDI8897 is currently in a Phase IIb clinical trial in prAlready a subscriber Login You have read all…
The company announced last week that a major Nordic study will begin using their PET imaging agent ABY-025. ABY-025 is a novel Affibody molecule imaging tracer that can identify HER2 status in breast cancer patients. The researchers will be investigating a new ABY-025 based method developed at UpAlready a subscriber…
